TITLE

Estimates of the duration of the early and late stage of gambiense sleeping sickness

AUTHOR(S)
Checchi, Francesco; Filipe, João A. N.; Haydon, Daniel T.; Chandramohan, Daniel; Chappuis, François
PUB. DATE
January 2008
SOURCE
BMC Infectious Diseases;2008, Vol. 8 Issue 1, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to predicting the impact of screening on transmission. Here, we outline a method to estimate these parameters. Methods: We first model the duration of stage 1 through survival analysis of untreated serological suspects detected during Médecins Sans Frontières interventions in Uganda and Sudan. We then deduce the duration of stage 2 based on the stage 1 to stage 2 ratio observed during active case detection in villages within the same sites. Results: Survival in stage 1 appears to decay exponentially (daily rate = 0.0019; mean stage 1 duration = 526 days [95%CI 357 to 833]), possibly explaining past reports of abnormally long duration. Assuming epidemiological equilibrium, we estimate a similar duration of stage 2 (500 days [95%CI 345 to 769]), for a total of nearly three years in the absence of treatment. Conclusion: Robust estimates of these basic epidemiological parameters are essential to formulating a quantitative understanding of sleeping sickness dynamics, and will facilitate the evaluation of different possible control strategies.
ACCESSION #
35709477

 

Related Articles

  • Gambiense sleeping sickness: re-emerging and soon untreatable? Van Nieuwenhove, Simon // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1283 

    Editorial. Comments on the return of sleeping sickness caused by Trypanosoma brucei gambiense. Deterioration and disruption of control activities; Problems on the implementation of active case detection and successful treatment; Gap between scientific progress and the implementation of...

  • Human African trypanosomiasis in endemic populations and travellers. Blum, J.; Neumayr, A.; Hatz, C. // European Journal of Clinical Microbiology & Infectious Diseases;Jun2012, Vol. 31 Issue 6, p905 

    Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b. rhodesiense (East African form) that are transmitted by the bite of the tsetse fly, Glossina spp.. Whereas most patients in endemic...

  • Epidemiology of Sleeping Sickness in Boffa (Guinea): Where Are the Trypanosomes? Kagbadouno, Moise Saa; Camara, Mamadou; Rouamba, Jeremi; Rayaisse, Jean-Baptiste; Traoré, Ibrahima Sory; Camara, Oumou; Onikoyamou, Mory Fassou; Courtin, Fabrice; Ravel, Sophie; de Meeûs, Thierry; Bucheton, Bruno; Jamonneau, Vincent; Solano, Philippe // PLoS Neglected Tropical Diseases;Dec2012, Vol. 6 Issue 12, p1 

    Human African Trypanosomiasis (HAT) in West Africa is a lethal, neglected disease caused by Trypanosoma brucei gambiense transmitted by the tsetse Glossina palpalis gambiensis. Although the littoral part of Guinea with its typical mangrove habitat is the most prevalent area in West Africa, very...

  • Human African Trypanosomiasis in the Democratic Republic of the Congo: A Looming Emergency? Hasker, Epco; Lutumba, Pascal; Chappuis, François; Kande, Victor; Potet, Julien; De Weggheleire, Anja; Kambo, Charles; Depoortere, Evelyn; Pécoul, Bernard; Boelaert, Marleen // PLoS Neglected Tropical Diseases;Dec2012, Vol. 6 Issue 12, p1 

    The author discusses the prevalence of Human African Trypanosomiasis (HAT) in the Democratic Republic of Congo (DRC). The author states that HAT is also known as sleeping sickness which is a parasitic disease which is fatal if left untreated. He notes that DRC is the worst affect country of HAT....

  • Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Pepin, Jacques; Khonde, Nzambi // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1284 

    Compares the effectiveness of 7 days of intravenous eflornithine with the standard 14-day regimen in the treatment of late-stage Trypanosoma brucei gambiense trypanosomiasis. Use of a randomized controlled trial; Death of some patients during treatment; Difference in response to treatment...

  • African Trypanosomes: Will the Twain Meet? Deresinski, Stan // Clinical Infectious Diseases;3/15/2006, Vol. 42 Issue 6, preceding p739 

    The article reports about African Trypanosomes, a sleeping sickness dieses. The human African trypanosomiasis disease exists in two forms: One is caused by Trypanosoma brucei subspecies ganbienese. Western and Central Africa is mostly affected by this dieses. Second is caused by T. brucei...

  • Sleeping bug: scientists identify drug resistance mechanism.  // Africa Health;Mar2012, Vol. 34 Issue 3, p12 

    The article focuses on the study conducted by the researchers in Greta Britain, which reveals several ways by which parasite Trypanosoma brucei can resist drugs used in treating sleeping sickness.

  • New Clues to Sleeping Sickness.  // JAMA: Journal of the American Medical Association;1/2/2013, Vol. 309 Issue 1, p20 

    The article informs that a new research conducted by the scientists of Germany, Sweden and the U.S. has explained the structure of a key enzyme named "Trypanosoma brucei cysteine protease cathepsin B," (TbCatB) from the parasite that causes African trypanosomiasis or sleeping sickness.

  • Estimating the burden of rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda. Fèvre, Eric M.; Odiit, Martin; Coleman, Paul G.; Woolhouse, Mark E. J.; Welburn, Susan C. // BMC Public Health;2008, Vol. 8 Issue 1, p96 

    Background: Zoonotic sleeping sickness, or HAT (Human African Trypanosomiasis), caused by infection with Trypanosoma brucei rhodesiense, is an under-reported and neglected tropical disease. Previous assessments of the disease burden expressed as Disability-Adjusted Life Years (DALYs) for this...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics